Regarding auranofin, its selectivity was very recently reported as comparable with chlorido-triphenylphosphanegold(I) complex and, more importantly, with cisplatin, as resulted from the studies using the B16–F10 metastatic skin melanoma, CT26-WT colon cancer, and 4T1 mammary adenocarcinoma cancer cells and their comparison with non-cancerous BHK21 kidney cells [46]. This evidence concerns the gene DDX53 and malignant colon neoplasm.